Ranibizumab In Pigment Epithelium Tears Secondary To Age-Related Macular Degeneration Study
NCT ID: NCT01914159
Last Updated: 2019-08-15
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
24 participants
INTERVENTIONAL
2013-02-28
2016-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD
NCT01269151
Efficacy Study of Ranibizumab on Patients With Age-related Macular Degeneration.
NCT01831947
Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration
NCT02140151
Microperimetry and Optical Coherence Tomography (OCT) With Lucentis for Diabetic Macular Edema (DME)
NCT00885794
Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration
NCT00395707
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ranibizumab
Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany)
Monthly intravitreal injections
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany)
Monthly intravitreal injections
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Written informed consent
Exclusion Criteria
* Ocular surgery of the study eye within 1 month before study recruitment
* Extensive subretinal fibrosis or retinal atrophy of the study eye
* Significant opacification of optical media of the study eye
* Uncontrolled glaucoma of the study eye
* Active ocular inflammation of the study eye
* Best-corrected visual acuity of the contralateral eye below 20/200
* Concurrent ocular or systemic therapy with other vascular endothelial growth factor (VEGF)-inhibitory drugs
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Bonn
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Frank G. Holz
Director, Department of Ophthalmology, University of Bonn
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Bonn, Department of Ophthalmology
Bonn, , Germany
University of München (LMU), Department of Ophthalmology
München, , Germany
Universityof Münster, Department of Ophthalmology
Münster, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
N-037.0156
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.